Research Oncology Solutions

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.

Research Oncology Solutions

Dr. K Govind Babu

MD, DM, Medical Oncologist

The Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) is the state of art of R&D wing of the Tata Memorial Centre. It is located in the picturesque settings at the foothills of the Sahyadri mountains in Kharghar, Navi Mumbai.  ACTREC comprises of, the Cancer Research…

Metastasis: The Everest of Cancer

The US Food and Drug Administration (FDA) approved 124 anticancer drugs for 374 indications between 2003 and 2021. An extensive review and analysis revealed that though they significantly reduced the risk of death by 27% and tumour progression by 43%, the median extension of both overall survival (OS) and progression-free survival (PFS) was limited to 2.80 and 3.30 months, respectively.

This is mainly because, though metastasis is responsible for the death of 90% of cancer patients, there are almost no treatments currently that can delay the process of metastasis. Current cancer treatments address most challenges: chemo and radiotherapy deal with proliferation, targeted therapy tackles initiation, and immunotherapy promotes the patient’s immunity. Unfortunately, there is nothing to delay the process of metastasis, which is synonymous with the terminal stage of cancer.

Problem Statement

The failure of several clinical candidates targeting metastasis has raised some pertinent questions that need to be answered for anti-metastasis drug discovery programs to be successful.

  • What is the IDEAL target that would translate into patients?
  • How to TRIAGE thousands of molecules without the right in vitro and in vivo models?
  • How to IDENTIFY primary tumour patients at higher risk for metastasis for a clinical trial?

Paradoxically, many discovery programs on proliferation targets do not evaluate the target for its potential impact in impeding metastasis, thereby missing out on leads or candidates that could have delayed metastasis and, therefore, be positioned as a first line of treatment. Consequently, it is important to answer the following questions.

  • Does the current target of interest play any role in promoting metastasis?
  • Do the molecules under current development reduce metastasis independent of cell killing?
  • Could current libraries be screened on translational systems profiling complete metastasis biology?

Research Oncology Solutions

  • The three proprietary and patented (applied) approaches of Mestastop can answer most of the above questions.
  • The METAssay® platform answers drug discovery challenges by helping identify potential targets and profiling the relevance of any target or lead candidates in the metastatic cascade.
  • The METAssay® and METVivo® platforms form an ideal screening cascade to identify anti-metastatic molecules.
  • The METSCAN® platform gives translational relevance to the other platforms and offers an ex-vivo characterisation of patient primary tumours.

Research Oncology Solutions

  • The three proprietary and patented (applied) approaches of Mestastop can answer most of the above questions.
  • The METAssay® platform answers drug discovery challenges by helping identify potential targets and profiling the relevance of any target or lead candidates in the metastatic cascade.
  • The METAssay® and METVivo® platforms form an ideal screening cascade to identify anti-metastatic molecules.
  • The METSCAN® platform gives translational relevance to the other platforms and offers an ex-vivo characterisation of patient primary tumours.

Drug Discovery

Identification of novel-first-in class targets in translational settings.

Know More

Drug Repurposing

Combination of in-vitro, in-vivo, ex-vivo and retrospective clinical trials to identify safest Candidates to delay metastasis in adjuvant settings.

Know More

Clinical Translation

Machine learning-powered patented biochemical approach to ensure patient relevance for accurate pre-clinical study design, significantly enhancing probability of clinical trial success.

Know More

All clinical samples are tumour-review board approved and patient-consented along with Institutional Ethics Committee clearance. Following grant of all necessary approvals, the samples undergo detailed analysis, from mechanobiology to metabolic profiling.

Hello, world!

Cancer Information

What is Cancer? Cancer is a group of diseases associated with abnormal growth of cells. Without any check, the disease may keep on progressing ultimately leading to pre-mature death. Cancers can arise anywhere in the body and can affect people from all age groups, socio-economic strata and race. Cancer is the leading cause of morbidity and mortality in the world. According to data by International Agency for Research on Cancer, there were 18.1 million new cancer cases, 9.6 million cancer deaths with cancer in 2018 worldwide. In India, about 11.57 Lakhs of new cases of cancer are detected…
Read More
  • Home
  • Research Oncology Solutions
Linkedin Twitter Youtube